It should be highlighted that another recent study has demonstrated the efficacy of the pan-PI3K inhibitor, NVP-BKM120, in pre-clinical models of Ph+ B-ALL [52]. This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.